The Ups and Downs in Drug Design: Adventures in Medicinal Chemistry highlights the necessity for an integrative approach in medicinal chemistry and chemical biology. As medicinal chemistry is not a monolithic science, it is important to emphasize the other various disciplines that are required for successful drug design. This book presents the author’s own personal experience in this field and describes the "ups" and "downs" that come with drug discovery. It is an excellent companion text for graduate and postgraduate students who would like further insight into the parameters of drug design, including the challenges that come with the project. Key Features Illustrates "real-life" examples in medicinal chemistry Integrates the use of physical, chemical, and biological concepts that are important in drug design Highlights the "ups" and "downs" that come with drug discovery Aims to inspire students who may be struggling with the challenges and thought process in drug design Intends to be an excellent companion text for graduate and postgraduate students

The Ups and Downs in Drug Design: Adventures in Medicinal Chemistry highlights the necessity for an integrative approach in Medicinal Chemistry and Chemical Biology. As Medicinal Chemistry is not a monolithic science, it is important to emphasize the other various disciplines that are required for successful drug design. This book presents the authors' own personal experience in this field and describes the "ups" and "downs" that come with drug discovery. This book is an excellent companion text for graduate and postgraduate students who would like further insight into the parameters of drug design, including the challenges that come with the project. Key Features: Describes 'real life' examples in Medicinal Chemistry. Integrates the use of physical, chemical, and biological concepts that are important in drug design. Highlights the "ups" and "downs" that come with drug discovery. Aims to inspire students who may be struggling with the challenges and thought process in drug design. Intends to be an excellent companion text, illustrating real life experiences, for graduate and postgraduate students.

Frontiers in Drug Design and Discovery Volume 9 is a book series devoted to publishing the latest and the most important advances in drug design and discovery. Eminent scientists have contributed chapters focused on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, and structure-activity relationships. This book series should prove to be of interest to all pharmaceutical scientists who are involved in research in drug design and discovery and who wish to keep abreast of rapid and important developments in the field. The ninth volume of this series brings together reviews covering topics related to the treatment of neoplasms, systems biology, respiratory diseases among others. Topics included in this volume are: -Prognostic biomarkers in prostate cancer -Chemoresistance in cancer cells -GPCRS in systems and synthetic biology -Mechanisms of action of ribavirin in different diseases -Carbon nanotubes and drug targets -The role of phosphatase I inhibitors in Minkowski spaces -Phosphodiesterase targeting for treating respiratory diseases

This book provides a comprehensive examination of the newest biopharmaceutical drugs. Among the drugs discussed are ones in the categories of monoclonal antibodies for in-vivo use, cytokines, growth factors, enzymes, immunomodulators, thrombolytics, and immonotherapies including vaccines. Additionally, the volume examines new and emerging technologies, and contains a review of the Human Genome Project.

The PCP's Bicentennial Edition Remington: The Science and Practice of Pharmacy, Twenty Third Edition, offers a trusted, completely updated source of information for education, training, and development of pharmacists. Published for the first time with Elsevier, this edition includes coverage of biologics and biosimilars as uses of those therapeutics have increased substantially since the previous edition. Also discussed are formulations, drug delivery (including prodrugs, salts, polymorphism. With clear, detailed color illustrations, fundamental information on a range of pharmaceutical science areas, and information on new developments in industry, pharmaceutical industry scientists, especially those involved in drug discovery and development will find this edition of Remington an essential reference. Intellectual property professionals will also find this reference helpful to cite in patents and resulting litigations. Additional graduate and postgraduate students in Pharmacy and Pharmaceutical Sciences will refer to this book in courses dealing with medicinal chemistry and pharmaceutics. - Contains a comprehensive source of principles of drug discovery and development topics, especially for scientists that are new in the pharmaceutical industry such as those with trainings/degrees in chemistry and engineering - Provides a detailed source for formulation scientists and compounding pharmacists, from produg to excipient issues - Updates this excellent source with the latest information to verify facts and refresh on basics for professionals in the broadly defined pharmaceutical industry

Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective thoroughly examines the current state of pharmaceutical research and development by providing chemistry-based perspectives on biomedical research, drug hunting and innovation. The book also considers the interplay of stakeholders, consumers, and the drug firm with attendant factors, including those that are technical, legal, economic, demographic, political, social, ecological, and infrastructural. Since drug research can be a high-risk, high-payoff industry, it is important to researchers to effectively and strategically manage the drug discovery process. This book takes a closer look at increasing pre-approval costs for new drugs and examines not only why these increases occur, but also how they can be overcome to ensure a robust pharmacoeconomic future. Written in an engaging manner and including memorable insights, this book is aimed at redirecting the drug discovery process to make it more efficient and cost-effective in order to achieve the goal of saving countless more lives through science. A valuable and compelling resource, this is a must-read for all students and researchers in academia and the pharmaceutical industry. - Considers drug discovery in multiple R&D venues, including big pharma, large biotech, start-up ventures, academia, and nonprofit research institutes - Analyzes the organization of pharmaceutical R&D, taking into account human resources considerations like recruitment and configuration, management of discovery and development processes, and the coordination of internal research within, and beyond, the organization, including outsourced work - Presents a consistent, well-connected, and logical dialogue that readers will find both comprehensive and approachable

Frontiers in Anti-Cancer Drug Discovery is an Ebook series devoted to publishing the latest and the most important advances in Anti-Cancer drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery, including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The Ebook series should prove to be of interest to all pharmaceutical scientists involved in research in Anti-Cancer drug design and discovery. Each volume is devoted to the major advances in Anti-Cancer drug design and discovery. The Ebook series is essential reading for all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Considerable progress has been made in our healthcare system, in particular with respect to sensitive diagnostic tools, reagents and very effective and precise drugs. On the other hand, high-throughput screening technology can screen vast numbers of compounds against an array of targets in a very short time, and leads thus - tained can be further explored. In developing countries, the exploding population exerts pressure not only on natural resources but also on the human population - self, whose members strive to become successful and advance in society. This leads to increased blood pressure, anxiety, obesity-associated lipid disorders, cardiov- cular diseases and diabetes. Most of these diseases result in disturbed family life, including sexual behaviour. Despite technological developments, herbal drugs still occupy a preferential place in a majority of the population in the Third World and terminal patients in the West. Herbal drugs, in addition to being cost effective and easily accessible, have been used since time immemorial and have passed the test of time without having any side effects. The multitarget effects of herbs (holistic approaches) are the fun- mental basis of their utilization. This approach is already used in traditional systems of medicine like Ayurveda, which has become more popular in the West in recent years. However, the integration of modern science with traditional uses of herbal drugs is of the utmost importance if ones wishes to use ancient knowledge for the betterment of humanity.

About half of all species under threat of extinction in the world today are plants. The loss of plant biodiversity is disturbing for many reasons, but especially because it is a reflection of the growing disconnect between humans and nature. Plants have been used for millennia in traditional systems of healing and have held a significant place in drug development for Western medicine as well. Despite the recent dominance of synthetic drug production, natural product discovery remains the backbone of drug development. As the diversity of life on Earth is depleted and increasing numbers of species become lost to extinction, we continue to lose opportunities to achieve advances in medicine. Through stories of drug revelation in nature and forays into botany, human behavior, and conservation, Kara Rogers sheds light on the multiple ways in which humans, medicine, and plants are interconnected. With accessible and engaging writing, she explores the relationships between humans and plants, relating the stories of plant hunters of centuries past and examining the impact of human activities on the environment and the world's biodiversity. Rogers also highlights the role that plant-based products can play in encouraging conservation and protecting the heritage and knowledge of indigenous peoples. Out of Nature provides a fresh perspective on modern drug innovation and its relationship with nature. The book delves into the complexity of biophilia—the innate human attraction to life in the natural world—and suggests that the reawakening of this drive is fundamental to expanding conservation efforts and improving medicine. Rogers's examination of plants, humans, and drug discovery also conveys a passionate optimism for the future of biodiversity and medicine. Including a collection of hand-drawn maps and plant illustrations created by the author, this well-researched narrative will inspire as well as inform.

For the first time in history, there is now hope for treating neurological disorders that had previously been considered untreatable. The remarkable confluence of events that has heralded this is the focus of Neurotherapeutics in the Era of Translational Medicine. This anthology, written by many of the prominent scientists and researchers in the field of biotechnology, recounts the breathtaking advances that are revolutionizing treatment for disorders such as amyotrophic lateral sclerosis?, spinal muscular atrophy, multiple sclerosis, Parkinson's disease, myasthenia gravis, migraine, and glioblastoma. The "story behind the story" of these translational efforts is told, with authors depicting the ups and downs encountered on the path of their drug discovery and development effort. In parallel with this path, advances in identifying novel biomarkers and disease models are summarized, as are contemporary issues focusing on clinical trial design, bioethics, innovative funding strategies, and collaborations between government and academia in an effort to facilitate breakthrough treatments. The book is written by members of the biotech and pharmaceutical ecosystem for those who belong to it and aspire to become part of it. - Comprehensive review on the progress of translational research in neurotherapeutics for neurologic disorders - Discusses important issues in clinical trials such as design and ethical issues - Written for neuroscientists, neurologists and pharmacologists